Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Tislelizumab by BeiGene for Gallbladder Cancer: Likelihood of Approval
Tislelizumab is under clinical development by BeiGene and currently in Phase II for Gallbladder Cancer. According to GlobalData, Phase II...
Tislelizumab by BeiGene for Androgen-Sensitive Prostate Cancer: Likelihood of Approval
Tislelizumab is under clinical development by BeiGene and currently in Phase II for Androgen-Sensitive Prostate Cancer. According to GlobalData, Phase...
Tislelizumab by BeiGene for Natural Killer Cell Lymphomas: Likelihood of Approval
Tislelizumab is under clinical development by BeiGene and currently in Phase II for Natural Killer Cell Lymphomas. According to GlobalData,...
Tislelizumab by BeiGene for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Tislelizumab is under clinical development by BeiGene and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...
Tislelizumab by BeiGene for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
Tislelizumab is under clinical development by BeiGene and currently in Phase II for Squamous Non-Small Cell Lung Cancer. According to...
Tislelizumab by BeiGene for Oral Cavity (Mouth) Cancer: Likelihood of Approval
Tislelizumab is under clinical development by BeiGene and currently in Phase II for Oral Cavity (Mouth) Cancer. According to GlobalData,...
Tislelizumab by BeiGene for Oropharyngeal Cancer: Likelihood of Approval
Tislelizumab is under clinical development by BeiGene and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase II...
Tislelizumab by BeiGene for Laryngeal Cancer: Likelihood of Approval
Tislelizumab is under clinical development by BeiGene and currently in Phase II for Laryngeal Cancer. According to GlobalData, Phase II...
Tislelizumab by BeiGene for Hypopharyngeal Cancer: Likelihood of Approval
Tislelizumab is under clinical development by BeiGene and currently in Phase II for Hypopharyngeal Cancer. According to GlobalData, Phase II...
Tislelizumab by BeiGene for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
Tislelizumab is under clinical development by BeiGene and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According to GlobalData,...
Tislelizumab by BeiGene for Ureter Cancer: Likelihood of Approval
Tislelizumab is under clinical development by BeiGene and currently in Phase I for Ureter Cancer. According to GlobalData, Phase I...
Tislelizumab by BeiGene for Urethral Cancer: Likelihood of Approval
Tislelizumab is under clinical development by BeiGene and currently in Phase I for Urethral Cancer. According to GlobalData, Phase I...
Tislelizumab by BeiGene for Muscle Invasive Bladder Cancer (MIBC): Likelihood of Approval
Tislelizumab is under clinical development by BeiGene and currently in Phase II for Muscle Invasive Bladder Cancer (MIBC). According to...
Tislelizumab by BeiGene for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Tislelizumab is under clinical development by BeiGene and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase...
Tislelizumab by BeiGene for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
Tislelizumab is under clinical development by BeiGene and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to GlobalData,...
Tislelizumab by BeiGene for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
Tislelizumab is under clinical development by BeiGene and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According to GlobalData,...
Tislelizumab by BeiGene for Marginal Zone B-cell Lymphoma: Likelihood of Approval
Tislelizumab is under clinical development by BeiGene and currently in Phase II for Marginal Zone B-cell Lymphoma. According to GlobalData,...
Tislelizumab by BeiGene for Metastatic Colorectal Cancer: Likelihood of Approval
Tislelizumab is under clinical development by BeiGene and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase...
Tislelizumab by BeiGene for Metastatic Melanoma: Likelihood of Approval
Tislelizumab is under clinical development by BeiGene and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II...
Tislelizumab by BeiGene for Colon Cancer: Likelihood of Approval
Tislelizumab is under clinical development by BeiGene and currently in Phase II for Colon Cancer. According to GlobalData, Phase II...